Enhanced anti-tumour immunity requires the interplay between resident and circulating memory CD8 + T cells
Michel Enamorado 1 , Salvador Iborra 1 , Elena Priego 1 2 , Francisco J Cueto 1 2 , Juan A Quintana 1 , Sarai Martínez-Cano 1 , Ernesto Mejías-Pérez 3 , Mariano Esteban 3 , Ignacio Melero 4 5 , Andrés Hidalgo 1 6 , David Sancho 1
The goal of successful anti-tumoural immunity is the development of long-term protective immunity to prevent relapse. Infiltration of tumours with CD8+ T cells with a resident memory (Trm) phenotype correlates with improved survival.
However, the interplay of circulating CD8+ T cells and Trm cells remains poorly explored in tumour immunity. Using different vaccination strategies that fine-tune the generation of Trm cells or circulating memory T cells, here we show that, while both subsets are sufficient for anti-tumour immunity, the presence of Trm cells improves anti-tumour efficacy.
Transferred central memory T cells (Tcm) generate Trm cells following viral infection or tumour challenge. Anti-PD-1 treatment promotes infiltration of transferred Tcm cells within tumours, improving anti-tumour immunity. Moreover, Batf3-dependent dendritic cells are essential for reactivation of circulating memory anti-tumour response.
Our findings show the plasticity, collaboration and requirements for reactivation of memory CD8+ T cells subsets needed for optimal tumour vaccination and immunotherapy.
CITA DEL ARTÍCULO Nat Commun. 2017 Jul 17;8:16073. doi: 10.1038/ncomms16073